- Home
- MDGL vs BAX Comparison
MDGL vs BAX Comparison
Compare MDGL & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | BAX |
|---|---|---|
| Founded | 2011 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MDGL | BAX |
|---|---|---|
| Price | $542.35 | $16.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 9 |
| Target Price | ★ $674.45 | $22.13 |
| AVG Volume (30 Days) | 331.2K | ★ 8.7M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $180,133,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $58.28 | $1.90 |
| Revenue Next Year | $46.80 | $2.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $265.00 | $15.73 |
| 52 Week High | $615.00 | $32.68 |
Technical Indicators
Market Signals| Indicator | MDGL | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 41.13 |
| Support Level | $535.33 | N/A |
| Resistance Level | $572.20 | $18.89 |
| Average True Range (ATR) | 26.64 | 0.68 |
| MACD | 11.53 | 0.07 |
| Stochastic Oscillator | 79.21 | 42.76 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.